Loading…
It is an open-label, randomized, parallel-group comparison trial to evaluate Fecal Microbiota Transplantation (FMT) vs control (mild to moderate UC were treated with mesalazine, and patients with severe UC were subsequently treated with corticosteroids for induction therapy and mesalazine for maintenance therapy) in 20 eligible patients with Ulcerative Colitis (UC) (1)
Clinical remission and mucosal remission. Clinical remission meant having a Mayo score of 2 or less, with each part of the score being 1 or less. Mucosal remission meant having a Mayo endoscopy score of 1 or less compared to the start. Clinical response was when the Mayo score dropped by 30% or more and by at least 3 points from the start by week 8. If the score for bloody purulent stool went down by 1 point or was 0 or 1, it was considered clinical improvement (1).
By week 8, 90% of the FMT group and 50% of the control group reached the main goal of the study. The Mayo score, which measures disease activity, was much lower in the FMT group compared to the control group at both week 4 and week 8 after treatment. However, there was no difference between the groups six months later. The average time patients stayed in remission was 24 months for both groups, with no significant difference (1).
Using just one fresh FMT treatment by itself is a good and safe way to help people with active Ulcerative Colitis (UC) get better for a long time without needing other medicines. It could also be a different starting treatment for those who have UC that keeps coming back or even for those who have UC for the first time (1).
(1)